Tesamorelin
low riskAlso: Egrifta · Egrifta SV · TH9507
Tesamorelin is the only FDA-approved GHRH analog, approved for visceral adiposity in HIV patients. Phase II trials ongoing for NASH in the general population. Well-tolerated with clear clinical evidence.
Reported Benefits
Visceral fat reduction (HIV)
Phase III: ~15% visceral fat reduction vs. placebo. FDA-approved indication.
NASH / liver fat reduction
Phase II (Stanley 2014): significant liver fat reduction and metabolic improvement.
Cognitive function (elderly)
Small trials suggest executive function improvement via IGF-1 elevation.
Mechanism of Action
GHRH analog — stimulates pulsatile GH secretion, increasing IGF-1 and reducing visceral fat accumulation via GH's lipolytic effects.
Key Clinical Studies
Only FDA-Approved GHRH Analog
Tesamorelin is unique — the only GHRH analog with FDA approval. The HIV lipodystrophy approval provides a regulatory precedent for GHRH-based therapy with implications for the broader metabolic disease pipeline.
Regulatory Status
FDA ApprovedFDA approved as Egrifta SV for HIV-associated lipodystrophy
Safety Profile
Side Effects
- •Injection site reactions
- •Fluid retention
- •Arthralgias
- •Glucose elevation (monitor)
Contraindications
- •Active malignancy
- •Pituitary disease
- •Pregnancy
Drug Interactions
- •Glucocorticoids
- •Insulin
Primary Uses
Related Peptides
Weekly Briefing
Regulatory updates + new study breakdowns.
For Practitioners
Do you prescribe Tesamorelin?
Get in front of patients who've already researched this protocol and are ready to consult. Featured listings from $199/mo.
Get Listed →